"
Team:Freiburg/Content/Team/Members
From 2014.igem.org
| Line 22: | Line 22: | ||
</div> | </div> | ||
</section> | </section> | ||
| + | |||
<section id="Team-Members"> | <section id="Team-Members"> | ||
<h1>Members</h1> | <h1>Members</h1> | ||
| - | <h2 id="Team- | + | <h2 id="Team-Jan-Ole-Ackermann">Jan Ole Ackermann</h2> |
<div class="row category-row"> | <div class="row category-row"> | ||
<div class="col-sm-6"> | <div class="col-sm-6"> | ||
| Line 31: | Line 32: | ||
<div class="col-sm-6"> | <div class="col-sm-6"> | ||
<figure> | <figure> | ||
| - | <img src="https://static.igem.org/mediawiki/2014/ | + | <img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg"> |
<figcaption> | <figcaption> | ||
<p class="header">Team</p> | <p class="header">Team</p> | ||
</figcaption> | </figcaption> | ||
| - | + | </figure> | |
</div> | </div> | ||
| - | + | </div> | |
| + | |||
| + | <h2 id="Team-Christoph-Bauern">Christoph Bauer</h2> | ||
| + | <div class="row category-row"> | ||
| + | <div class="col-sm-6"> | ||
| + | <figure> | ||
| + | <img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg"> | ||
| + | <figcaption> | ||
| + | <p class="header">Team</p> | ||
| + | </figcaption> | ||
| + | </figure> | ||
| + | </div> | ||
| + | <div class="col-sm-6"> | ||
| + | <p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | |||
</section> | </section> | ||
Revision as of 16:59, 9 October 2014
Team
We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.
Team
Members
Jan Ole Ackermann
We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.
Team
Christoph Bauer
Team
We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.
